N/A
N=52
Clinical Study for TONOREF III Tested to ANSI Z80.10-2014
Intraocular Pressure
Bottom Line
View on ClinicalTrials.gov: NCT07152808 ↗Enrolled (actual)
52
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Agreement of Intraocular Pressure — 18.4; 18.3 mmHg
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- NIDEK TONOREF III (Device); Haag-Streit Goldmann Manual Tonometer (Device)
- Age
- Adult, Older Adult · 22+ yrs
- Sex
- All
- Sponsor
- Nidek Co. LTD.
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Agreement of Intraocular Pressure |
18.4; 18.3 | — |
| SECONDARY The Numbers of Adverse Events |
— | — |
Summary
The primary objective of this clinical study was to show that tonometry values for TONOREF III, as the representative device of the NIDEK tonometer series, were comparable to the predicate device.
The secondary objective was to demonstrate that the test device was as safe as the predicate device.
Eligibility Criteria
Inclusion Criteria
Each subject had to have:
- been at least 22 years of age of either sex and any race or ethnicity;
- been willing and able to provide written informed consent prior to any study procedures being performed;
- been willing and able to follow all instructions and attend all study visits;
- corneal astigmatism of ≤3D and corneal thickness of 500-600 μm in at least one eye.
Exclusion Criteria
Each subject had to not to :
- have only one functional eye;
- have poor or eccentric fixation in the study eye;
- have corneal scarring or have had corneal surgery, including corneal laser surgery in the study eye
- have microphthalmos in the study eye;
- have buphthalmos in the study eye;
- be a contact lens wearer in the study eye;
- have dry eyes;
- be a lid squeezer - blepharospasm;
- have nystagmus in the study eye;
- have keratoconus in the study eye;
- have any other corneal or conjunctival pathology or infection in the study eye;
- use medication that affect IOP;
- current participation in other clinical trials;
- have a condition or a situation, which in the Investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation.
Data sourced from ClinicalTrials.gov (NCT07152808). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.